title: SUBFOVEAL CHOROIDAL THICKNESS AND VASCULAR DIAMETER IN ACTIVE AND RESOLVED CENTRAL SEROUS CHORIORETINOPATHY.
abstract: OBJECTIVE
  To determine the subfoveal choroidal thickness and analyze Haller's layer, Sattler's layer, and large choroidal vessel diameter in eyes with active central serous chorioretinopathy (CSC) and after resolution of CSC.
  
  
  METHODS
  Ocular and clinical features of 32 eyes with CSC were analyzed retrospectively from October 2014 to September 2015. Subfoveal choroidal thickness and thicknesses of Haller's layer and Sattler's layer were measured in the active and resolved states. The diameter of the subfoveal choroidal hyporeflective lumen (i.e., the large choroidal vessel in Haller's layer) was also measured.
  
  
  RESULTS
  The mean subfoveal choroidal thickness, mean thickness of Haller's layer, and mean choroidal vessel diameter were significantly less after the resolution of CSC (P < 0.001). However, the thickness of Sattler's layer did not change after the resolution of CSC (P = 0.731). There were no significant differences among the different treatment modalities.
  
  
  CONCLUSIONS
  After the resolution of CSC, the subfoveal choroidal thickness and thickness of Haller's layer declined, but the reduced diameter of subfoveal choroidal vessels accounted for only about half of the total thickness changes in the choroid. These results suggest that nonvascular smooth muscle cells might play a role in the thickening of the choroid during CSC and possibly in the pathogenesis and progression of CSC.
authors.affiliation: Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
authors.forename: Yoo-Ri
authors.initials: YR
authors.lastname: Chung
authors.affiliation: Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
authors.forename: Jong Wan
authors.initials: JW
authors.lastname: Kim
authors.affiliation: Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
authors.forename: Shin-Young
authors.initials: SY
authors.lastname: Choi
authors.affiliation: Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea.|Departments of Biomedical Sciences, and.
authors.forename: Sung Wook
authors.initials: SW
authors.lastname: Park
authors.affiliation: Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea.|Departments of Biomedical Sciences, and.|Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea.
authors.forename: Jeong Hun
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
authors.forename: Kihwang
authors.initials: K
authors.lastname: Lee
mesh_terms: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab / Q000008:administration & dosage; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D002829:Choroid / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods*; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012171:Retinal Vessels / Q000473:pathology*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000379:methods*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor